GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Insider Ownership

Virax Biolabs Group (Virax Biolabs Group) Insider Ownership : 0.00 % (As of Jun. 10, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Virax Biolabs Group's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Virax Biolabs Group's Institutional Ownership is 0.02%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Virax Biolabs Group's Float Percentage Of Total Shares Outstanding is 77.73%.


Virax Biolabs Group Insider Ownership Historical Data

The historical data trend for Virax Biolabs Group's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Insider Ownership Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Insider Ownership
- - - -

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Insider Ownership Get a 7-Day Free Trial - - - - -

Virax Biolabs Group Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.